Lutetium radionuclides

Panigone S, Nunn AD. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs a novel approach to radionuclide therapy. Quart. J. Nucl. Med. Mol. Imaging 2006 50 310-321. 

Lutetium-177 has been identified as a suitable radionuclide for targeted therapy of various malignant disorders. Some of the participants were introduced to the chemistry of Lu and the application of other therapeutic radionuclides for the first time. The sourcing of Lu, a radionuclide that can... 

Lutetium-177 is increasingly being viewed as a potential radionuclide for use in in vivo therapy because of its favourable decay characteristics. Lutetium-177 decays with a half-life of 6.73 d by emission of beta particles with maximum energies of 497 keV (78.6%), 384 keV (9.1%) and 176 keV (12.2%) to stable Hf. The emission of gamma photons of 113 keV (6.4%) and 208 keV (11%) with relatively low abundances provides advantages that allow simultaneous... 

The present studies were aimed at the development of laboratory evaluation techniques for studying the efficacy of therapeutic radiopharmaceuticals. The primary goal was to develop radiotherapeutic agents using the peptide-BFCA conjugate DOTA-Tyr -octreotate (DOTATATE). The radioisotopes used for the therapeutic preparations were Lu and °Y. Lutetium-177 was identified as an ideal radionuclide for... 

---